University of California San Francisco
Give to UCSF
Cancer immunotherapy is hindered by the fact that engineered immune cells often get worn out and depleted before they've killed a tumor. A UCSF team has identified mutations that give cancerous lymphoma T-cells their superpower and transfer those genes into engineered, therapeutic immune cells.
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T
The new JN.1 COVID-19 variant is now estimated to make up about 20% of cases in the United States. Three UCSF experts offer advice on vaccines, masking, and other ways to protect yourself.
Fortified stem cells. Enhanced memory. A longevity hormone. UCSF researchers are finding out whether we can cancel – or at least delay – old age.
Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.” The conference will take place online and in
A collaboration is between two biomedical researchers bridges the laboratory and clinic to advance the science of itch, allergy and asthma.
A phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
A study found that children who were recently diagnosed with type 1 diabetes need less supplemental insulin to keep their blood sugar in a healthy range if they use the immunotherapy drug teplizumab.
Scientists found that the nervous system tamps down allergic response, which could change how asthma, Crohn’s and other inflammatory diseases are treated.
Convergent evolutionary mechanisms shared by COVID-19 variants allow them to overcome both adaptive and innate immune system barriers.
The FDA recently approved the world’s first vaccines to prevent RSV for infants and elderly adults.
A new report from the Lancet Commission on tuberculosis releases recommendations, providing a path forward to turn the tide on this preventable, treatable and curable disease.
UCSF researchers are working across disease specialties. Diabetes researchers are looking at how oncologists use CAR T-cell therapy to reprogram a person’s immune system to attack cancer cells, for example. They hope to similarly reprogram the immune system to fight diabetes.
Long COVID symptoms can persist for a year after initial infection, or re-emerge months later after disappearing.
An experimental blood test that reflects injury to nerve cells from multiple sclerosis (MS) was found to work for children with MS and other neurological conditions, even when they are symptom-free.
A common mutation can help people infected with the COVID-19 virus avoid developing any symptoms.
Deaths among older adults with dementia fell starkly in nursing homes and long-term care centers after COVID-19 vaccinations became available, but remained high for those living at home.
UCSF infectious disease specialist Michael Peluso, MD, who co-leads one of the world’s oldest studies of long COVID, discusses the condition’s mysteries.
